Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Net Change in Cash

Last Annual Value

-17.82M

3-Year CAGR

-39%

5-Year CAGR

-10%

10-Year CAGR

-22%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Net Change in Cash

SLNO · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
-17.82M
N/AN/AN/A 
253.47M
45.8%N/A14.1%
458.35M
N/AN/A-9.7%
CELC logo
Celcuity Inc.
NASDAQ:CELC
143.19M
186.5%14.5%68.2%
141.96M
93.2%N/AN/A
139.13M
94.6%N/A50.7%
-10.53M
N/AN/AN/A
75.24M
-22.0%N/AN/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01